Piramal Pharma Shares Hits 52-Week High of ₹244: Key Metrics and Investment Outlook
Piramal Pharma has been in the spotlight recently due to its fluctuating share prices and notable financial updates. As of September 25, 2024, the share price of Piramal Pharma is ₹217.67, reflecting a decline of 1.75% from the previous day’s close of ₹231.44. This performance comes after a period of significant volatility in the stock market, particularly within the pharmaceutical sector.
Main Points
- 1 Current Piramal Pharma Shares and Market Overview
- 2 Piramal Pharma Shares Key Financial Metrics
- 3 Piramal Pharma Shares Recent Developments
- 4 Financial Performance Highlights
- 5 Piramal Pharma Shares Analyst Recommendations
- 6 Piramal Pharma Shares Technical Analysis
- 7 Piramal Pharma Shares Support and Resistance Levels
- 8 Piramal Pharma Shares Market Sentiment
- 9 Institutional Holdings
On this date, Piramal Pharma’s stock opened at ₹240 and reached a high of ₹244 during intraday trading, with a low of ₹236. The stock has shown a 52-week range between ₹88 and ₹244, indicating substantial growth over the past year. Despite this recent dip, the stock has appreciated by approximately 124.1% over the last year, showcasing its potential for long-term investors.
- Market Capitalization: ₹30,683.11 crore
- P/E Ratio: 1,123.78
- EPS (Earnings Per Share): ₹0.21
- Dividend Yield: 0%
- 52 Week High/Low: ₹243.99 / ₹87.50
The company reported a loss of ₹88.64 crore in its latest quarter (ending June 30, 2024), marking a shift from three consecutive profitable quarters. Despite this setback, Piramal Pharma’s annual revenue growth of 14.23% outperformed its three-year CAGR of 8.72%, highlighting resilience in its operational performance.
Financial Performance Highlights
Piramal Pharma’s recent quarterly results have drawn attention for several reasons:
- Revenue Growth: The company reported an increase in revenue from operations by 12% year-on-year, amounting to ₹1,951 crore in Q1 FY25.
- EBITDA Improvement: EBITDA grew by 31% year-on-year, reaching ₹221 crore with an EBITDA margin improvement of over 170 basis points compared to Q1 FY24.
- Successful FDA Inspections: The company successfully closed USFDA inspections at its Lexington facility with zero observations, reinforcing its commitment to quality and compliance.
Analysts have mixed sentiments regarding Piramal Pharma’s stock:
- Strong Buy Recommendations: Several analysts maintain a “Strong Buy” rating based on the company’s robust operational metrics and market position.
- Target Prices: Some investment firms have set target prices ranging from ₹115 to ₹180, indicating potential upside despite recent losses.
From a technical perspective, Piramal Pharma’s stock is positioned above key moving averages:
- 50-Day Moving Average: Approximately ₹238.77
- 200-Day Moving Average: Approximately ₹150.91
The stock’s current price is comfortably above these averages, suggesting bullish momentum in the short to medium term.
Investors should be aware of critical support and resistance levels:
| Support Level | Resistance Level |
|---|---|
| ₹218.70 | ₹241.99 |
| ₹205.96 | ₹252.54 |
| ₹195.41 | ₹265.28 |
These levels are crucial for traders looking to enter or exit positions effectively.
The overall market sentiment towards Piramal Pharma remains cautiously optimistic despite recent challenges:
- The decline in share price might present a buying opportunity for investors looking for long-term growth.
- Increased demand for pharmaceutical products and services continues to drive interest in the sector.
Institutional Holdings
Recent reports indicate a decline in institutional holdings in Piramal Pharma, which could be seen as a negative indicator by some investors. However, this trend may also reflect broader market dynamics rather than company-specific issues.
Disclaimer: The information given in this article is from investment experts and brokerage companies, they do not represent Local Haryana. Before taking any investment related decision, you must consult a certified expert.
